deltatrials
Active Not Recruiting OBSERVATIONAL NCT01382082

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy (CANTAB)

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment, at Six Month Follow-Up, and Long-Term Follow-Ups

Sponsor: National Cancer Institute (NCI)

Updated 22 times since 2017 Last updated: Apr 22, 2026 Started: Jul 14, 2011 Primary completion: Jul 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and Lymphoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 22 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Jun 2023 · 12 months · monthly snapshot~Jun 2023 – ~May 2024 · 11 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Feb 2026 · 10 months · monthly snapshot~Feb 2026 – ~Apr 2026 · 3 months · monthly snapshotApr 28, 2026 – present · 59 days · daily API

Change History

22 versions recorded
  1. Apr 28, 2026 — Present [daily]

    Active Not Recruiting

    Status: Enrolling By InvitationActive Not Recruiting

  2. Feb 2026 — Apr 2026 [monthly]

    Enrolling By Invitation

  3. Apr 2025 — Feb 2026 [monthly]

    Enrolling By Invitation

  4. Sep 2024 — Apr 2025 [monthly]

    Enrolling By Invitation

  5. Jul 2024 — Sep 2024 [monthly]

    Enrolling By Invitation

Show 17 earlier versions
  1. May 2024 — Jul 2024 [monthly]

    Enrolling By Invitation

  2. Jun 2023 — May 2024 [monthly]

    Enrolling By Invitation

  3. Jun 2022 — Jun 2023 [monthly]

    Enrolling By Invitation

  4. Dec 2021 — Jun 2022 [monthly]

    Enrolling By Invitation

  5. Sep 2021 — Dec 2021 [monthly]

    Enrolling By Invitation

    Status: Active Not RecruitingEnrolling By Invitation

  6. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting

  7. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting

  8. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting

  9. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting

  10. Mar 2019 — Dec 2019 [monthly]

    Active Not Recruiting

  11. Nov 2018 — Mar 2019 [monthly]

    Active Not Recruiting

  12. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting

  13. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting

  14. Apr 2018 — May 2018 [monthly]

    Active Not Recruiting

    Phase: NANone

  15. Aug 2017 — Apr 2018 [monthly]

    Active Not Recruiting NA

  16. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting NA

    Status: RecruitingActive Not Recruiting

  17. Jan 2017 — Jun 2017 [monthly]

    Recruiting NA

    First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

Cognitive impairments in cancer patients represent an important clinical problem. Studies to date estimating prevalence of difficulties in memory, executive function, and attention deficits have been limited by small sample sizes and many have lacked healthy control groups. More information is needed on promising biomarkers and allelic variants that may help to determine the etiology of impairment, identify those most vulnerable to impairment, and develop interventions for these difficulties. This is a longitudinal observational study of cognitive function in breast cancer and lymphoma patients receiving chemotherapy to better understand the prevalence of cognitive difficulties (i.e., problems with memory, executive function, and attention) in these populations.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Rochester NCORP Research Base
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .